ResearcherWuhan Union HospitalActive in the last 2 years
Penglin Pan
Matched on ORCID iD 0000-0002-0922-5631; OpenAlex author ID A5021158665. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 14
2022: 4 papers · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 5
- RNF43 deficiency activates YBX1-MYC-driven oxidative phosphorylation in pancreatic cancer. First author DOI 10.1016/j.canlet.2026.218560↗
- ITGA2 overexpression inhibits DNA repair and confers sensitivity to radiotherapies in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.215855↗
- HDAC5 Loss Enhances Phospholipid-Derived Arachidonic Acid Generation and Confers Sensitivity to cPLA2 Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-21-4362↗
- Safety and Efficacy of Irreversible Electroporation in Locally Advanced Pancreatic Cancer: An Evaluation from a Surgeon's Perspective. First author DOI 10.3390/cancers14225677↗
- HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer. Co-author DOI 10.7150/thno.69444↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Gengdu Qin · 4 shared papers, 2022–2026 · strength 0.69
- Paper RNF43 deficiency activates YBX1-MYC-driven oxidative phosphorylation in pancreatic cancer. DOI 10.1016/j.canlet.2026.218560↗
- Paper ITGA2 overexpression inhibits DNA repair and confers sensitivity to radiotherapies in pancreatic cancer. DOI 10.1016/j.canlet.2022.215855↗
- Paper HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer. DOI 10.7150/thno.69444↗
- Heshui Wu · 4 shared papers, 2022 · strength 0.61
- Paper Safety and Efficacy of Irreversible Electroporation in Locally Advanced Pancreatic Cancer: An Evaluation from a Surgeon… DOI 10.3390/cancers14225677↗
- Paper ITGA2 overexpression inhibits DNA repair and confers sensitivity to radiotherapies in pancreatic cancer. DOI 10.1016/j.canlet.2022.215855↗
- Paper HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer. DOI 10.7150/thno.69444↗
- Haixin Yu · 3 shared papers, 2022–2026 · strength 0.55
- Paper RNF43 deficiency activates YBX1-MYC-driven oxidative phosphorylation in pancreatic cancer. DOI 10.1016/j.canlet.2026.218560↗
- Paper HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer. DOI 10.7150/thno.69444↗
- Paper HDAC5 Loss Enhances Phospholipid-Derived Arachidonic Acid Generation and Confers Sensitivity to cPLA2 Inhibition in Pan… DOI 10.1158/0008-5472.can-21-4362↗
- Yingke Zhou · 3 shared papers, 2022 · strength 0.41
- Paper ITGA2 overexpression inhibits DNA repair and confers sensitivity to radiotherapies in pancreatic cancer. DOI 10.1016/j.canlet.2022.215855↗
- Paper HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer. DOI 10.7150/thno.69444↗
- Paper HDAC5 Loss Enhances Phospholipid-Derived Arachidonic Acid Generation and Confers Sensitivity to cPLA2 Inhibition in Pan… DOI 10.1158/0008-5472.can-21-4362↗
- Dianyun Ren · 3 shared papers, 2022 · strength 0.41
- Paper ITGA2 overexpression inhibits DNA repair and confers sensitivity to radiotherapies in pancreatic cancer. DOI 10.1016/j.canlet.2022.215855↗
- Paper HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer. DOI 10.7150/thno.69444↗
- Paper HDAC5 Loss Enhances Phospholipid-Derived Arachidonic Acid Generation and Confers Sensitivity to cPLA2 Inhibition in Pan… DOI 10.1158/0008-5472.can-21-4362↗
- Jian Shen · 2 shared papers, 2022 · strength 0.34
- Paper Safety and Efficacy of Irreversible Electroporation in Locally Advanced Pancreatic Cancer: An Evaluation from a Surgeon… DOI 10.3390/cancers14225677↗
- Paper HDAC5 Loss Enhances Phospholipid-Derived Arachidonic Acid Generation and Confers Sensitivity to cPLA2 Inhibition in Pan… DOI 10.1158/0008-5472.can-21-4362↗
- Yi Zhou · 1 shared paper, 2026 · strength 0.28
- Jun Zhao · 1 shared paper, 2022 · strength 0.20
- Chen Zhou · 1 shared paper, 2022 · strength 0.14
- Shikai Zhu · 1 shared paper, 2022 · strength 0.14
- Jingyuan Zhao · 1 shared paper, 2022 · strength 0.14
- Yan Sun · 1 shared paper, 2022 · strength 0.14
- Taoyu Chen · 1 shared paper, 2022 · strength 0.14
- Xin Jin · 1 shared paper, 2022 · strength 0.14
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.